Stocktoria
ANAPTYSBIO, INC ANAB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2017-01-26
ANAPTYSBIO, INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 20.4% | -125.9% | -958.3% | -1119.4% | -89.9% |
| Net margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% |
| FCF margin | 8.4% | -148.7% | -708.8% | -718.9% | -74.8% |
| Return on assets | -3.6% | -30.0% | -36.2% | -21.1% | -9.0% |
| Return on equity | -35.6% | -204.9% | -185.7% | -49.1% | -16.2% |
| Current ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 |
| Revenue growth | 157.0% | 432.0% | 66.8% | -83.7% | -15.8% |
Source: SEC EDGAR filings · CIK 0001370053 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.